The induction of insulin release only in the presence of high glucose (thus avoiding the risk of hypoglycaemia) and modulation of the early phase of insulin secretion account for the increasing use of GLP-1 mimetics in the treatment of type 2 diabetes (T2D) [16, 22–25]. Here, INS is linked to Hypoglycemia.